Background Platelets play an important role in the pathophysiology of acute coronary syndromes. The interaction between the platelet glycoprotein lb receptor and von Willebrand factor is a critical event allowing platelet adhesion and aggregation and subsequent thrombus formation in vessels with high shear rates and damaged endothelium. Therefore, we tested the hypotheses that VCL, an antagonist of von Willebrand-glycoprotein lb binding domain, (1) attenuates/ abolishes cyclic flow variations in stenosed, endotheliuminjured coronary arteries in nonhuman primates and (2) reduces botrocetin-induced platelet aggregation in vitro after intravenous in vivo administration.
. The baboons were divided into three groups. One group (n=8) received a bolus of VCL (4 mg/kg IV) followed by an infusion (6 mg * kg-1* h-') for 90 minutes (schedule A). Another group (n=6) received a 2-mg/kg bolus followed by an infusion of 3 mg* kg`1 h-1 for 90 minutes (schedule B). The third group received a placebo infusion of normal saline. Under dosing schedule A, cyclic flow variations were abolished in 7 of 8 baboons after 33 ± 18 minutes and markedly attenuated in 1. The frequency of cyclic flow variations fell from 18±9.4 per hour during the control period to 1±2.5 per hour after VCL infusion, P<.002. After cessation of infusion, cyclic flow variations remained abolished in 5 of 7 I n stenosed coronary arteries with endothelial damage, we and others have suggested that plateletmediated obstruction is an important pathophysiological mechanism for the conversion of chronic, stable animals for >3 hours and returned in 2 of 7 after 2 to 2.5 hours. Under schedule B, cyclic flow variations were abolished in 3 of 6 baboons and markedly reduced in the remainder. The number of cyclic flow variations fell from 17±4.8 per hour during the control period to 5±4.9 per hour after the VCL infusion, P<.001. The cyclic flow variations returned spontaneously at 38±40 minutes under this dosing schedule. Placebo infusion of saline had no effect on cyclic flow frequency or severity. VCL administration was associated with slight prolongation in bleeding time and a reduction in botrocetin-induced platelet aggregation. The bleeding time increased from a control time of 88±32 to 276±204 seconds, P<.03, and from 142±28 to 176±36 seconds, P=.056, for schedules A and B, respectively. VCL decreased platelet aggregation in response to botrocetin (20 ,tg/mL), from a control value of 66±30.3 to 33±31.3 fl, P<.05, and from 64±23.5 to 46±15.8 fl, P=.006, for dosing schedules A and B, respectively.
Conclusions Therefore, administration of a peptide fragment corresponding to von Willebrand-glycoprotein Ib binding domain (1) is effective in abolishing cyclic flow variations in stenosed, endothelium-injured coronary arteries and (2) reduces platelet aggregation in vivo in response to botrocetin in nonhuman primates. (Circulation. 1994; 90:2976 -2981 Key Words * von Willebrand factor * glycoproteins a platelets * blood flow to unstable coronary disease syndromes. [1] [2] [3] [4] When there is loss of endothelial integrity, platelet adhesion is a critical step in the response of platelets, allowing interaction with exposed subendothelial components of the damaged vessel with circulating platelets. 5, 6 The von Willebrand factor molecule plays a pivotal role in the process of platelet adhesion, by virtue of its ability to interact with both the subendothelial components and the glycoprotein lb receptor on platelets. The formation of platelet aggregates is especially dependent on the glycoprotein lb-von Willebrand factor interaction in blood vessels exposed to high shear stresses. 
Study Protocol
The recombinant von Willebrand factor fragment (VCL), Leu-504 to Lys-728, was expressed in Escherichia coli and purified as previously described (Fig 1) . ' 8) with ice-cold sterile water to a concentration of approximately 2 mg/mL. The solution was further diluted in normal (N-)saline to provide a suitable volume for infusion. The baboons were divided into three groups. One group (n=4) received placebo (90-minute infusion of N-saline), and two groups received VCL. One group (n=8) received VCL as a bolus of 4 mg/kg followed by a 90-minute infusion of 6 mg . kg`. h`(schedule A), and the other received a bolus of 2 mg/kg followed by a 90-minute infusion of 3 mg* kg-' h( schedule B). The baboons were observed for 3 hours after the end of the infusion.
Measurements of blood coagulation, hemostasis, hematocrit, and botrocetin-induced platelet aggregation were made before the administration of either VCL or placebo and again 90 minutes later at the end of the infusion. Activated (Fig 2) . No statistically significan hematocrits, heart rates, or sys pressures were observed. In the cyclic flow variations were com turned spontaneously (mean, 38 Blood samples were drawn i mination of VCL levels duri Samples were drawn at 5, 30, 4 the onset of infusion and at 10, 120, 150, and 180 minutes aftf sion. The mean plasma concen VCL was measured during the infusion. After cessation of the infusion, the clearance half-time of VCL from the plasma was 22 minutes (Fig 3B) In the canine heart, severe coronary artery stenoses associated with endothelial injury promote cyclic reductions in coronary flow, manifested by marked reductions in coronary blood flow followed by spontaneous increases in coronary flow. 16 In this study, we have shown that by administration of a peptide fragment of the von Willebrand-glycoprotein Ia binding domain, cyclic variations can be abolished or greatly diminished. The presumed mechanism by which this occurs is the inhibition of the interaction of the platelet glycoprotein Ib receptor and the surface-bound von Willebrand factor. This prevents platelet activation and aggregation and also the release of proaggregatory and vasoconstrictor substances responsible for cyclic flow variations.
The pharmacokinetic studies demonstrated that a steady state was achieved rapidly. VCL was cleared rapidly from the plasma, with a half-time of 20 to 30 minutes. When it was given by intravenous bolus followed by infusion, therapeutic effects of VCL occurred within 20 to 30 minutes after administration. Under dosing schedule A, the duration of VCL effects persisted for >2 hours, with cyclic flow variations returning only after infusion of epinephrine in some of the baboons. Under the lowerdose schedule B, the effects of VCL were less pronounced and their duration shorter.
Effect of VCL on Platelet Function
In a previous in vitro study, VCL inhibited ristocetinand botrocetin-induced platelet aggregation in a static the surgical wounds or at puncture sites in the experimental animals. Although it is unlikely that the degree of prolongation in these experiments would result in any significant hemostatic problems, the effect may be of importance when VCL is used in combination with antiplatelet and thrombolytic agents.
The fall in platelet count was unexpected, and the mechanism is not known. The decrease in platelet count was small and did not fall outside the lower limit of normal. It seems unlikely that it resulted from the experimental model, since there was no significant change in the platelet count in the placebo group. The decrease did not appear to be dose related, since the change was similar in both dosing schedules. Different production batches of VCL were used during this study, but no relation between the VCL batch used and the fall in platelet count was identified. It is possible that the fall in platelet count is immunologic in origin, with sequestration of platelets within the reticuloendothelial system. However, we have no evidence to support this hypothesis at this time. This finding requires further evaluation to determine whether it is a transient, selflimited phenomenon and to elucidate the underlying mechanism.
Study Limitations
Because of the expense and relative difficulty in obtaining the animals used in this study, the number of animals in each group is small. We used a paired t test design to help control for the extraneous variation that occurs in experimental models such as the one used in this study. For these reasons, the power of statistical analyses performed and the conclusions that can be drawn from these data are limited. Nevertheless, administration of VCL had a dramatic effect on the cyclic flow variations in this model of coronary stenosis and endothelial injury.
The clinical relevance of this experimental model has been questioned. However, there is increasing evidence that cyclic abnormalities in coronary flow also occur in at least some patients with severe coronary artery disease, which supports the likely pertinence of this model to acute coronary syndromes in man.21 '22 Conclusions
The role of platelet adhesion and aggregation in the conversion of chronic and stable to acute and unstable coronary artery syndromes is well documented. The interaction between the von Willebrand factor molecule of damaged endothelium and the glycoprotein lb receptor of circulating platelets is an important one. It initiates the thrombotic process in the presence of damaged vessels with high shear stress, as found in the coronary arterial system. Therefore, inhibition of this process is an attractive possibility for the prevention and treatment of acute coronary disease syndromes. This peptide fragment may provide an effective and relatively specific means of largely preventing or interrupting the thrombotic process, and it may represent a new class of antithrombotic compounds.
